A majority of deaths from Friedreich's ataxia are associated with heart complications. A new treatment years in the making could provide some much-needed relief.
Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.
The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.
The study, presented at the Society of Interventional Radiology Annual Scientific Meeting, marks one of the first to use freezing on large tumors in the breast.
While the American College of Cardiology's annual meeting has historically had a more clinical focus, presentations at this year's conference in Atlanta will spend much more time looking at the business side of things.
Eric Secemsky, MD, from Beth Israel Deaconess Medical Center and Harvard Medical School, says a lack of hands-on training and reimbursement challenges are hindering the adoption of IVUS.
